Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates

Stock Track

Feb 11, 2025

Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.

The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.

Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1102531516"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102531516\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102531516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102531516","market":"us","top_or_hot":-1,"title":"Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates","media":"Stock Track","content":"<p>Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.</p>\n\n<p>The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.</p>\n\n<p>Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-11 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.</p>\n\n<p>The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.</p>\n\n<p>Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARVN","symbol_name":"Arvinas Holding Company LLC","start_time":0,"source_url":"","article_id":"1102531516","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102531516","pubTimestamp":1739279028,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARVN":"Arvinas Holding Company LLC"},"translate_title":"股票赛道Arvinas盘前飙升5.17%，因积极的季度业绩和有希望的药物更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARVN":1},"content_text":"Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.\nThe biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.\nFurthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}